보고서 요약(국문)

시장 개요
전 세계 인슐린 저항성 시장 규모는 2023년 XX백만 달러였으며, 2030년까지 XX백만 달러에 이를 것으로 예상됩니다. 예측 기간(2023-2030년) 동안 연평균 성장률(CAGR)은 4.2%입니다.
인슐린 저항성은 정상적인 인슐린 농도에 대한 생리적 반응이 비정상적으로 느린 상태를 말합니다. 근육, 지방, 간의 세포가 인슐린에 제대로 반응하지 못하고 혈액 속 포도당을 에너지로 활용하지 못하면 인슐린 저항성이라고 합니다. 그 결과 췌장은 더 많은 인슐린을 분비하게 되고, 혈당 수치가 점차 상승합니다. 제2형 당뇨병, 고콜레스테롤혈증, 고혈압, 비만은 인슐린 저항성 증후군의 대표적인 증상입니다.
시장 동향
전 세계 인슐린 저항성 시장 성장을 이끄는 주요 요인은 좌식 생활 방식의 증가와 당뇨병 유병률 증가입니다. 또한, 의료비 상환 및 기타 가격 관련 정부 규제, 성장하는 의료 부문, 그리고 최첨단 의료 시술에 대한 대중의 인식 제고 또한 시장 성장을 견인할 것으로 예상됩니다.

좌식 생활 방식의 증가와 당뇨병 유병률 증가.
좌식 생활 방식의 증가와 당뇨병 유병률 증가로 인해 인슐린 저항성 관련 시장이 확대되고 있습니다. 고령화, 좌식 생활 방식의 증가, 비만 발생률 증가로 인해 인슐린 저항성 환자가 증가할 것으로 예상됩니다. 좌식 생활 방식의 확산과 신체 활동 감소는 이러한 우려를 더욱 증폭시키고 있습니다. 포도당 내성 검사는 포도당을 투여한 후 혈액 샘플을 채취하여 체내에서 포도당이 얼마나 빨리 제거되는지 평가하는 검사입니다. 일반적으로 이 검사는 당뇨병, 인슐린 저항성, 췌장 베타 세포 활동 저하, 반응성 저혈당증, 말단비대증 및 기타 드문 탄수화물 대사 이상을 확인하는 데 사용됩니다.
국제당뇨병연맹(International Diabetes Federation)은 2021년까지 5억 3,700만 명의 성인(20~79세)이 당뇨병을 앓을 것으로 추정합니다. 2030년에는 전 세계적으로 6억 4,300만 명, 2045년에는 7억 8,300만 명이 당뇨병을 앓게 될 것으로 예상됩니다. 당뇨병 환자 4명 중 3명은 저소득 및 중소득 국가에 거주합니다. 성인 당뇨병 환자는 전체 인구의 거의 절반(2억 4천만 명)을 차지합니다. 당뇨병 유병률이 전 세계적으로 증가함에 따라 시장이 성장하고 있습니다.
제한적인 의약품 선택권과 인슐린 저항성에 대한 정보 부족은 시장 성장을 저해할 것으로 예상됩니다.
인슐린 저항성 치료제의 부족과 인슐린 저항성에 대한 지식 부족은 인슐린 저항성 관련 시장 성장을 저해할 것으로 예상되는 요인 중 일부입니다. 또한, 개발도상국과 신흥국에서 더 많은 의료비 지원이 필요합니다.
코로나19 영향 분석
코로나19 팬데믹은 전 세계 경제 전망, 운영 및 위기 대응 전략에 부정적인 영향을 미쳤습니다. 특정 기저 질환이 있는 사람들은 코로나19로 인한 중증 질환 발병 위험이 더 높을 수 있습니다. 당뇨병, 심장 질환, 비만, 만성 신장 질환 등이 그 예입니다. 미국 질병통제예방센터(CDC)의 연구에 따르면, 제2형 당뇨병 환자는 코로나19 관련 중증 질환 발병 위험이 더 높은 것으로 나타났습니다. 코로나19 팬데믹으로 인해 접근성과 경제성이 더욱 중요해졌으며, 이는 당뇨병 치료제 개발 전략에도 영향을 미쳤습니다.
팬데믹 기간 동안 환자들이 인슐린을 구할 수 있도록 미국 시장에서 활동하는 수많은 제약 회사들이 다양한 지원 프로그램을 발표했습니다. 코로나19 팬데믹의 사회경제적 영향으로 많은 당뇨병 환자들이 의료 서비스에 접근하기 어려워짐에 따라, 제약 회사들은 인슐린 및 항당뇨병제에 대한 수요 증가로 인해 당뇨병 환자들을 위한 새롭고 접근성이 높은 치료법을 개발할 기회를 더 많이 얻게 되었습니다.
세그먼트 분석
인슐린 저항성 치료를 위한 고농축 인슐린 제품 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
지난 몇 년 동안 미국에서는 당뇨병 환자 치료를 위한 고농축 인슐린 제품이 더욱 다양하게 출시되었습니다. 이러한 약물은 일반적인 U-100 인슐린보다 밀리리터당 더 많은 인슐린 단위를 함유하고 있어, 환자들이 치료 순응도를 높이고 혈당 조절을 개선할 수 있는 다양한 선택지를 제공할 수 있습니다. 모든 고농축 인슐린은 제품 식별과 정확한 투여가 용이한 특수 프리필드 펜 기기에 담겨 제공됩니다.
최근 100단위/mL 이상의 고농축 인슐린과 특수 장비의 개발로 당뇨병 환자는 기저 및 식후 인슐린 보충을 위한 새로운 치료 선택지를 갖게 되었습니다. 고농축 인슐린 제제의 농도는 속효성 식후 효과를 나타내는 2배(인슐린 리스프로 200단위/mL)부터 기저 및 속효성 식후 효과를 모두 나타내는 5배(휴먼 레귤러 인슐린 500단위/mL)까지 다양합니다. 데글루덱 200단위/mL와 글라진 300단위/mL는 장효성 기저 인슐린입니다. 고농축 인슐린은 주사량과 주사 횟수를 줄이고, 경우에 따라 약동학적 및 약력학적 특성을 변형하여 인슐린 투여를 간소화하기 위해 개발되었습니다. 시장은 제품 개발과 사용 증가에 따라 움직입니다.

지리적 분석
북미는 전 세계 인슐린 저항성 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
2021년 앨라배마대학교 버밍엄 캠퍼스의 연구에 따르면 당뇨병이 없는 젊은 성인의 거의 40%가 인슐린 저항성을 가지고 있습니다. 인슐린 저항성은 신체가 인슐린에 제대로 반응하지 않아 혈당을 에너지로 사용하지 못하는 질환입니다. 인슐린 제조업체 수익의 거의 50%가 미국 내에서 발생하는 미국에서는 비용 문제가 가장 큰 걸림돌입니다.
캐나다 보건 연구소(CIHR)는 영양, 대사 및 당뇨병 연구소(INMD)의 지휘 아래 당뇨병에 대한 최첨단 연구에 자금을 지원하고 있습니다. CIHR은 2019년 "인슐린 100년: 당뇨병 퇴치를 위한 캐나다 연구 가속화"라는 중요한 사업을 시작하여 캐나다 연구자들이 협력자들과 함께 당뇨병 및 그 합병증의 예방 및 치료를 위한 새로운 접근법을 찾을 수 있도록 연구 자금을 확대하고 있습니다. 이 지역 시장 성장은 강력한 시장 경쟁, 증가하는 의료 GDP 지출, 그리고 인슐린 치료에 대한 정부의 재정 지원 확대에 주로 영향을 받습니다.
경쟁 환경
인슐린 저항성 시장은 글렌마크 파마슈티컬스, 아스트라제네카, 브리스톨-마이어스 스큅, 일라이 릴리, 머크, 노바 노르디스크, 테바 파마슈티컬스, 사노피, 글락소스미스클라인, 마일란 등 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 주요 기업들은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 채택하여 시장 성장에 기여하고 있습니다. 예를 들어, 글렌마크 파마슈티컬스는 2022년 10월 성인 제2형 당뇨병 치료를 위한 티아졸리딘디온 로베글리타존을 출시한다고 발표했습니다. 글렌마크 파마슈티컬스(Glenmark Pharmaceuticals)의 발표에 따르면, 인도인들 사이에서 인슐린 저항성이 높은 빈도로 나타나고 있어, LOBG는 인슐린 저항성 당뇨병 환자 중 조절되지 않는 제2형 당뇨병 환자에게 매력적인 치료 옵션이 될 수 있습니다.
글렌마크 파마슈티컬스
개요: 글렌마크 파마슈티컬스(Glenmark Pharmaceuticals Ltd.)는 신약(NCE) 개발을 주력으로 하는 회사입니다. 이 회사는 브랜드 의약품과 제네릭 의약품을 모두 개발 및 판매합니다. 종양학, 피부과, 호흡기 질환은 이 회사의 의약품 사업부가 다루는 치료 전문 분야 중 일부에 불과합니다. 또한 경구 피임약, 당뇨병, 심혈관 질환을 포함한 다양한 치료 분야에 사용됩니다. 이 회사는 활성 의약품 성분(API)을 생산 및 유통합니다. 글렌마크는 체코, 미국, 아르헨티나, 인도에 생산 시설을 보유하고 있습니다.
제품 포트폴리오:
LOBG: 티아졸리딘디온 계열 약물인 로베글리타존은 인슐린 민감도를 증가시킵니다. 이 항당뇨병제는 LOBG라는 상품명으로 판매될 예정입니다. 이 약은 로베글리타존 0.5mg을 함유하고 있으며, 지시대로 하루 한 알 복용해야 합니다. LOBG는 인슐린 저항성이 있는 제2형 당뇨병 환자에게 바람직한 치료 대안입니다.
글로벌 인슐린 저항성 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The Global Insulin Resistance Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.2% during the forecast period (2023-2030).
Insulin resistance is an abnormally slow physiologic reaction to normal insulin concentrations. When cells in the muscles, fat, and liver do not respond to insulin well and cannot utilize glucose from the blood for energy, this condition is known as insulin resistance. The pancreas produces more insulin as a result. Blood sugar levels rise over time. Type 2 diabetes, cholesterol, blood pressure, and obesity are just a few of the conditions that are a part of insulin resistance syndrome.
Market Dynamics
The major factors driving the global insulin resistance market are the growing sedentary lifestyle and expanding diabetes prevalence, the market will also be driven by reimbursement and other pricing-related government regulations, and the growing healthcare sector and increased public knowledge of cutting-edge medical procedures will propel the market.
Growing sedentary lifestyle and expanding diabetes prevalence.
The market for insulin resistance is expanding as a result of rising sedentary lifestyles and rising diabetes prevalence. Patients with insulin resistance are expected to increase due to an aging population, an increase in sedentary lifestyles, and an increase in obesity incidence. Concerns are increased by sedentary lifestyle adoption and a decline in physical activity. In the glucose tolerance test, blood samples are taken after glucose is administered to assess how rapidly it is eliminated from the body. Typically, the test is used to check for diabetes, insulin resistance, decreased beta cell activity, reactive hypoglycemia, acromegaly, and other less common abnormalities of carbohydrate metabolism.
According to International Diabetes Federation estimates that 537 million adults (20-79 years old) will have diabetes by 2021. By 2030, there will be 643 million people worldwide living with diabetes, and by 2045, there will be 783 million; 3 in 4 individuals with diabetes reside in low- and middle-income nations. Adults with diabetes make up almost one in two people (240 million). The market is driven by the rising prevalence of diabetes globally.
Limited pharmaceutical choices and lack of information on insulin resistance is expected to hamper the market’s growth.
The availability of few medications and the lack of knowledge about insulin resistance are some of the factors expected to hinder the growth of the insulin resistance market. Additionally, the industry needs more reimbursement in developing and rising nations.
COVID-19 Impact Analysis
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. An increased risk of developing a serious disease from COVID-19 may exist in individuals with specific underlying medical disorders. Diabetes, cardiac issues, obesity, and chronic kidney disease are some ailments. According to a CDC specific study, type 2 diabetes patients had a higher risk of developing severe COVID-19-related illnesses, according to the CDC. Accessibility and affordability have increased in priority due to the COVID-19 pandemic, which also affected diabetic developer strategies.
To assist patients in getting insulin during the pandemic, numerous pharmaceutical companies operating in the US market have publicly publicized programs. When many diabetes patients may not have access to healthcare due to the socio-economic impact of the COVID-19 epidemic. Drug manufacturers have a greater chance to produce novel and more approachable therapies for the diabetic population due to the increased demand for insulin and anti-diabetics.
Segment Analysis
Concentrated insulin products of Insulin resistance the segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Over the past few years, there have been more concentrated insulin products available in the US to treat diabetic patients. These medications may give patients options to improve glycemic control with treatment regimens that may increase their adherence to therapy since they contain more units of insulin per milliliter than typical U-100 insulins. All concentrated insulins are offered in distinctive prefilled pen devices that make it easy to identify the product and administer doses precisely.
Recent developments in concentrated insulins (exceeding 100 units/mL) and specialized equipment have given persons with diabetes new treatment choices for basal and prandial insulin supplementation. The concentrations of concentrated insulin formulations range from 2-fold (insulin lispro 200 units/mL), which has a fast-acting prandial effect, to 5-fold (human regular insulin 500 units/mL), which has basal and short-acting prandial activities. Degludec 200 units/mL and glargine 300 units/mL are two long-acting basal insulins. Concentrated insulins were created with the intention of simplifying the administration of insulin by lowering the volume and frequency of injections and, in certain cases, by utilizing modified pharmacokinetic and pharmacodynamic features. The market is driven by the development of the product and its use.
Geographical Analysis
North America holds the largest market share in the global Insulin resistance market.
Nearly 40% of young adults without diabetes, according to research from the University of Alabama at Birmingham in 2021, have insulin resistance, a disease in which the body does not respond to insulin as it should and cannot use blood glucose for energy. In the United States, where nearly 50% of the earnings for the manufacturers of insulin come from within the nation, the cost aspect is the biggest concern.
Under the direction of the Institute of Nutrition, Metabolism, and Diabetes, the Canadian Institutes of Health Research is funding cutting-edge research into diabetes (CIHR-INMD). 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes is a significant initiative that the Institute launched in 2019 to increase funding for Canadian researchers so they can work with collaborators to find novel approaches to preventing and treating diabetes and its complications. The region's market growth is primarily influenced by powerful market rivals, increasing healthcare GDP spending, and improved government reimbursement for insulin treatment.
Competitive Landscape
The insulin resistance market is moderately competitive with local and global companies’ presence Glenmark Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Nova Nordisk, Teva Pharmaceuticals, Sanofi, GlaxoSmithKline, Mylan and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in October 2022, Glenmark Pharmaceuticals announced the introduction of Thiazolidinedione Lobeglitazone for the treatment of type 2 diabetes in adults. According to a statement from Glenmark Pharmaceuticals, there is a high frequency of insulin resistance among Indians, making LOBG an appealing treatment option for treating insulin-resistant diabetic patients with uncontrolled Type 2 diabetes
Glenmark Pharmaceuticals.
Overview: Glenmark Pharmaceuticals Ltd. (Glenmark) 's primary objective is developing novel chemical entities (NCEs). The company creates and sells both branded and generic formulations. Oncology, dermatology, and respiratory are just a few therapeutic specialties covered by the company's formulations division. Additionally, it is used in numerous therapeutic contexts, including oral contraceptives, diabetes, and cardiovascular conditions. The firm produces and distributes active medicinal components (APIs). Glenmark has production sites in the Czech Republic, the United States, Argentina, and India.
Product Portfolio:
LOBG: Thiazolidinedione Drug called lobeglitazone that increases insulin sensitivity The anti-diabetic drug will be offered for sale under the trade name LOBG . It has 0.5 mg of lobeglitazone and should be taken one daily as directed. LOBG is a desirable medical alternative for patients with Type 2 diabetes who are insulin resistant.
The global Insulin resistance market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing sedentary lifestyle and expanding diabetes prevalence
4.1.1.2. The market will also be driven by reimbursement and other pricing-related government regulations
4.1.2. Restraints:
4.1.2.1. Limited pharmaceutical choices and lack of information on insulin resistance
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Biguanides
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Glucagon-like Peptide 1 (GLP-1) Receptor Agonists
7.4. Concentrated Insulin Products
7.5. Sodium-glucose cotransporter 2 (SGLT2) inhibitors
7.6. Dipeptidyl peptidase-4 (DPP-4) inhibitor
7.7. Others
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Branded
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Generics
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Glenmark Pharmaceuticals
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. AstraZeneca
12.3. Bristol-Myers Squibb
12.4. Eli Lilly and Company
12.5. Merck & Co.
12.6. Nova Nordisk
12.7. Teva Pharmaceuticals
12.8. Sanofi
12.9. GlaxoSmithKline
12.10. Mylan.
LIST NOT EXHAUSTIVE
13. Global Insulin resistance Market – DataM
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us

언급된 주요 기업들

Glenmark Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Nova Nordisk, Teva Pharmaceuticals, Sanofi, GlaxoSmithKline, Mylan.

표 목록 (Tables)

List of Tables Table 1 Global Insulin Resistance Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Insulin Resistance Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Insulin Resistance Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Insulin Resistance Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Insulin Resistance Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Insulin Resistance Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 7 Global Insulin Resistance Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Insulin Resistance Market Value, By Indication, 2022-2033 (US$ Billion)

Table 9 Global Insulin Resistance Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Insulin Resistance Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 11 Global Insulin Resistance Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Insulin Resistance Market Value, By Region, 2022-2033 (US$ Billion)

Table 13 North America Insulin Resistance Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 14 North America Insulin Resistance Market Value, By Indication, 2022-2033 (US$ Billion)

Table 15 North America Insulin Resistance Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 16 North America Insulin Resistance Market Value, By Country, 2022-2033 (US$ Billion)

Table 17 Europe Insulin Resistance Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 18 Europe Insulin Resistance Market Value, By Indication, 2022-2033 (US$ Billion)

Table 19 Europe Insulin Resistance Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 20 Europe Insulin Resistance Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Insulin Resistance Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Insulin Resistance Market Value, By Indication, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Insulin Resistance Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Insulin Resistance Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 South America Insulin Resistance Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 26 South America Insulin Resistance Market Value, By Indication, 2022-2033 (US$ Billion)

Table 27 South America Insulin Resistance Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 28 South America Insulin Resistance Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Middle East and Africa Insulin Resistance Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 30 Middle East and Africa Insulin Resistance Market Value, By Indication, 2022-2033 (US$ Billion)

Table 31 Middle East and Africa Insulin Resistance Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 32 Middle East and Africa Insulin Resistance Market Value, By Country, 2022-2033 (US$ Billion)

Table 33 GLENMARK PHARMACEUTICALS LTD.: Overview

Table 34 GLENMARK PHARMACEUTICALS LTD.: Product Portfolio

Table 35 GLENMARK PHARMACEUTICALS LTD.: Key Developments

Table 36 Novo Nordisk A/S: Overview

Table 37 Novo Nordisk A/S: Product Portfolio

Table 38 Novo Nordisk A/S: Key Developments

Table 39 Sanofi: Overview

Table 40 Sanofi: Product Portfolio

Table 41 Sanofi: Key Developments

Table 42 Eli Lilly and Company: Overview

Table 43 Eli Lilly and Company: Product Portfolio

Table 44 Eli Lilly and Company: Key Developments

Table 45 Teva Pharmaceutical Industries Ltd.: Overview

Table 46 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 47 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 48 Mylan N.V.: Overview

Table 49 Mylan N.V.: Product Portfolio

Table 50 Mylan N.V.: Key Developments

Table 51 AstraZeneca: Overview

Table 52 AstraZeneca: Product Portfolio

Table 53 AstraZeneca: Key Developments

Table 54 Boehringer Ingelheim International GmbH: Overview

Table 55 Boehringer Ingelheim International GmbH: Product Portfolio

Table 56 Boehringer Ingelheim International GmbH: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Insulin Resistance Market Share, By Drug Class, 2024 & 2033 (%)

Figure 3 Global Insulin Resistance Market Share, By Indication, 2024 & 2033 (%)

Figure 4 Global Insulin Resistance Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Insulin Resistance Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Insulin Resistance Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 7 Biguanides Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 8 Glucagon-like Peptide 1 (GLP-1) Receptor Agonists Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 9 Concentrated Insulin Products Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 10 Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 11 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 12 Others Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 13 Global Insulin Resistance Market Y-o-Y Growth, By Indication, 2023-2033 (%)

Figure 14 Type 2 Diabetes Indication in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 15 Prediabetes Indication in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 16 Gestational Diabetes Mellitus Indication in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 17 Polycystic Ovary Syndrome Indication in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 18 Obesity Indication in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 19 Others Indication in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 20 Global Insulin Resistance Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 21 Hospital Pharmacies Distribution Channel in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 22 Retail Pharmacies Distribution Channel in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 23 Online Pharmacies Distribution Channel in Global Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 24 Global Insulin Resistance Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 25 North America Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 26 North America Insulin Resistance Market Share, By Drug Class, 2024 & 2033 (%)

Figure 27 North America Insulin Resistance Market Share, By Indication, 2024 & 2033 (%)

Figure 28 North America Insulin Resistance Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 29 North America Insulin Resistance Market Share, By Country, 2024 & 2033 (%)

Figure 30 Europe Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 31 Europe Insulin Resistance Market Share, By Drug Class, 2024 & 2033 (%)

Figure 32 Europe Insulin Resistance Market Share, By Indication, 2024 & 2033 (%)

Figure 33 Europe Insulin Resistance Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 34 Europe Insulin Resistance Market Share, By Country, 2024 & 2033 (%)

Figure 35 Asia-Pacific Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 36 Asia-Pacific Insulin Resistance Market Share, By Drug Class, 2024 & 2033 (%)

Figure 37 Asia-Pacific Insulin Resistance Market Share, By Indication, 2024 & 2033 (%)

Figure 38 Asia-Pacific Insulin Resistance Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 39 Asia-Pacific Insulin Resistance Market Share, By Country, 2024 & 2033 (%)

Figure 40 South America Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 41 South America Insulin Resistance Market Share, By Drug Class, 2024 & 2033 (%)

Figure 42 South America Insulin Resistance Market Share, By Indication, 2024 & 2033 (%)

Figure 43 South America Insulin Resistance Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 44 South America Insulin Resistance Market Share, By Country, 2024 & 2033 (%)

Figure 45 Middle East and Africa Insulin Resistance Market Value, 2022-2033 (US$ Billion)

Figure 46 Middle East and Africa Insulin Resistance Market Share, By Drug Class, 2024 & 2033 (%)

Figure 47 Middle East and Africa Insulin Resistance Market Share, By Indication, 2024 & 2033 (%)

Figure 48 Middle East and Africa Insulin Resistance Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 49 GLENMARK PHARMACEUTICALS LTD.: Financials

Figure 50 Novo Nordisk A/S: Financials

Figure 51 Sanofi: Financials

Figure 52 Eli Lilly and Company: Financials

Figure 53 Teva Pharmaceutical Industries Ltd.: Financials

Figure 54 Mylan N.V.: Financials

Figure 55 AstraZeneca: Financials

Figure 56 Boehringer Ingelheim International GmbH: Financials

글로벌 인슐린 저항성 시장 – 2023-2030

Global Insulin Resistance Market - 2023-2030